Avalo Therapeutics, Inc. filings document clinical, financial, capital-structure, and governance disclosures for a biotechnology issuer developing IL-1β-based therapies. Recent 8-K reports cover abdakibart LOTUS trial materials in hidradenitis suppurativa, operating and financial results, investor presentation updates, and material agreements related to milestone obligations from the AlmataBio acquisition.
The company's proxy materials describe shareholder voting matters, board composition, executive compensation, equity awards, and governance practices. Avalo's filing record also includes disclosure categories tied to common stock and pre-funded warrant financing, Nasdaq inducement awards, risk and operating updates, and formal reporting of material events affecting its clinical-stage business.
Avalo Therapeutics, Inc. ownership disclosure: Logos Global Management and related reporting persons report beneficial ownership of 1,675,000 shares of Common Stock, equal to 3.2% of the class. The calculation uses 52,565,517 shares outstanding as of May 8, 2026.
The filing states the position comprises 675,000 shares of Common Stock and options to acquire 1,000,000 shares. Reporting persons disclaim group membership and sole beneficial ownership; shared voting and dispositive power are reported for the listed entities and individual.
Avalo Therapeutics, Inc. ownership disclosure: RA Capital Management, L.P., RA Capital Healthcare Fund, L.P., Peter Kolchinsky and Rajeev Shah report shared beneficial ownership totaling 2,455,655 shares as of March 31, 2026 and state a 9.99% ownership position under a conversion cap.
The Fund directly holds 662,968 shares and Series C preferred stock convertible into up to 2,483,099 shares, subject to a Beneficial Ownership Blocker that prevents conversion above the 9.99% threshold. Share counts reference 22,788,452 shares outstanding as of March 18, 2026.
OrbiMed Advisors LLC reports beneficial ownership of 475,165 shares of Avalo Therapeutics common stock, representing 2.1% of the class as of 03/31/2026. The filing is an Amendment No. 3 to a Schedule 13G/A and states the shares are held with shared voting and dispositive power.
Avalo Therapeutics disclosed Schedule 13G/A ownership details from reporting persons led by Biotechnology Value Fund and affiliates. The filing lists specific beneficial ownership counts and applies a 9.99% Beneficial Ownership Limitation that restricts conversion of Series C Preferred Stock. The Reporting Persons jointly report holdings tied to convertible Series C Preferred Stock convertible into common shares and attribute aggregated positions through partnership and GP relationships.
The filing states 22,788,452 Shares outstanding as of March 18, 2026 was used to compute percentages and that 726 Series C Preferred shares are convertible into 726,000 Shares (conversion limited to 715,000 Shares by the Beneficial Ownership Limitation). Reported beneficial ownership examples: BVF 1,258,371 Shares (≈5.4%), BVF2 919,912 Shares (≈4.0%), Trading Fund OS 141,562 Shares (<1%).
Avalo Therapeutics: Schedule 13G/A reporting beneficial ownership. Caligan Partners LP and David Johnson filed an amended Schedule 13G/A reporting beneficial ownership of 1,635,023 shares of Avalo Therapeutics common stock, representing 7.2% of the class based on 22,788,452 shares outstanding as of March 18, 2026.
The filing attributes the position to Caligan and to Mr. Johnson as managing partner; the shares are reported with shared voting and shared dispositive power. The filing is signed by Mr. Johnson on behalf of both reporting persons.
Avalo Therapeutics Inc filing reports that T. Rowe Price Investment Management, Inc. holds 2,162,684 shares of common stock, equal to 9.5% of the class. The filer states it denies beneficial ownership of the securities and the filing reflects ownership and voting/dispositive powers as reported.
Avalo Therapeutics, Inc. ownership disclosure: Avoro Capital Advisors LLC and Behzad Aghazadeh report beneficial ownership of 1,410,000 shares of Common Stock, representing 5.75% of the class. The percentage uses a base of 24,502,449 shares outstanding as of March 26, 2026. The disclosure is filed on Schedule 13G and lists sole voting and dispositive power over the reported shares by the reporting persons.
Avalo Therapeutics reports that Affinity Asset Advisors, LLC and Michael Cho beneficially own 1,340,840 shares of Common Stock as of March 31, 2026. This position represents approximately 5.5% of the company's Common Stock based on 24,502,449 shares outstanding as of March 26, 2026. The filing states the shares are directly held by Affinity Healthcare Fund, LP, with the Adviser exercising sole voting and dispositive power over those shares.
Avalo Therapeutics reported a net loss of $19.6 million for the quarter ended March 31, 2026, wider than $13.1 million a year earlier, as it increased investment in its pipeline. Research and development spending rose to $14.0 million, driven by manufacturing and clinical costs for its lead IL‑1β antibody abdakibart.
The company announced positive Phase 2 LOTUS data in hidradenitis suppurativa, where abdakibart met the primary HiSCR75 endpoint at both doses, with about 42.5% combined responders versus 25.6% on placebo. On March 31, 2026, Avalo held $82.0 million in cash and short-term investments, then strengthened its balance sheet with a follow-on equity and pre-funded warrant offering generating approximately $431.3 million in gross proceeds and expected net proceeds of about $405.0 million. Management now expects current cash resources and this capital raise to fund operations into 2029 while advancing abdakibart into a registrational Phase 3 program.
Avalo Therapeutics reported a larger net loss for the first quarter of 2026 while delivering positive clinical and financing milestones. Net loss was $19.6 million, compared with $13.1 million a year earlier, as research and development spending increased to $14.0 million and general and administrative expenses to $6.9 million.
The company ended March 31, 2026 with $82.0 million in cash, cash equivalents and short-term investments, and later completed an underwritten public offering of common stock and pre-funded warrants for gross proceeds of $431.3 million, or approximately $405.0 million net, extending its cash runway into 2029.
Clinically, Avalo reported positive topline Phase 2 LOTUS results for its lead asset abdakibart in moderate to severe hidradenitis suppurativa, meeting the primary endpoint at both doses with around 42% absolute improvement in HiSCR75 response rates at Week 16 versus 25.6% for placebo, and plans to advance into a registrational phase 3 program.